5-Benzylidenehydantoin manufacturers
|
| 5-Benzylidenehydantoin Basic information |
Product Name: | 5-Benzylidenehydantoin | Synonyms: | (5E)-5-Benzylidene-2,4-imidazolidinedione;2,4-Imidazolidinedione, 5-(phenylmethylene)-;5-phenylmethylenehydantoin;TIMTEC-BB SBB007867;RARECHEM AP KH 0029;Benzylidene hydantoin;5-Benzylidendhydantoin;5-BENZYLIDENEHYDANTOIN ---YELLOWISH POWDER--- | CAS: | 3775-01-7 | MF: | C10H8N2O2 | MW: | 188.18 | EINECS: | | Product Categories: | | Mol File: | 3775-01-7.mol | |
| 5-Benzylidenehydantoin Chemical Properties |
Melting point | 220.00°C - 222.00°C | density | 1.329g/cm3 | InChI | InChI=1S/C10H8N2O2/c13-9-8(11-10(14)12-9)6-7-4-2-1-3-5-7/h1-6H,(H2,11,12,13,14) | InChIKey | UDTSPKADQGPZFS-UHFFFAOYSA-N | SMILES | C1(=O)NC(=CC2=CC=CC=C2)C(=O)N1 |
| 5-Benzylidenehydantoin Usage And Synthesis |
Description | Derivatives of 5-Benzylidenehydantoin are well known of their various attractive bioactivities such as anticancer, antimicrobial, antidiabetic and tyrosinase inhibitor. UPR1024 belongs to a new class of EGFR inhibitors characterized by a hydantoin nucleus and a 5-benzylidene substituent having a double bond conjugated with a carbonyl group on the hydantoin ring. The compound had antiproliferative and proapoptotic effects when tested on the non-small cell lung cancer cell line A549[1-2]. | Biological Activity | 5-Benzylidenehydantoins inhibited the EGFR kinase and exhibited an antiproliferative action on A431 human epidermoid carcinoma cells. The conjugated exo-cyclic double bond at the C5 position appeared essential for both EGFR and cell growth inhibition, indicating that the 5-benzylidene hydantoin core would be a suitable scaffold for generating new antiproliferative compounds[3]. | References |
[1] Haq, K. U. et al. “Synthesis of 5-benzylidene-hydantoin and 5-benzylidene-creatinine derivatives under mixed catalyst systems of urea-p-toluenesulfonic acid (Urea-PTSA) and guanidine hydrochloride-triethylamine (GnHCl-TEA).”(2020). [2] Andrea Cavazzoni. “Dual mechanisms of action of the 5-benzylidene-hydantoin UPR1024 on lung cancer cell lines.” Molecular Cancer Therapeutics 7 2 (2008): 361–70.
|
| 5-Benzylidenehydantoin Preparation Products And Raw materials |
|